CD274 and hepatocellular carcinoma: Regarding immune checkpoints molecules (Fig. 2), the combinatorial of bevacizumab as VEGF inhibitor and PD-L1 inhibitor atezolizumab showed promising outcomes in advanced HCC cases as approved by FDA for HCC therapy [77].